STAT January 17, 2025
Joe Grogan

Price controls are a surefire way to crush innovation

President Biden took a groundbreaking step in proposing to cover GLP-1 obesity medications under Medicare and Medicaid in November. But on Friday, his administration announced that Wegovy, one of these drugs, would be subject to price controls. This is a surefire way to crush innovation and discourage new entrants to this important new class of medicines that could help millions of Americans.

GLP-1s, or glucagon-like peptide-1 receptor agonists, are...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
Medicare’s Selection Of 15 More Drugs For Price Negotiation Puts Spotlight Back On IRA
How Many Physicians Have Opted Out of the Medicare Program? - 2
MedPAC Members Vote to Recommend Pay Hikes for Physicians and Hospitals
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
MedPAC wants Medicare physician reimbursement tied to Medicare Economic Index

Share This Article